ABL Bio Inc
KOSDAQ:298380
ABL Bio Inc
Research & Development
ABL Bio Inc
Research & Development Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
Company | Research & Development | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
---|---|---|---|---|---|---|
A
|
ABL Bio Inc
KOSDAQ:298380
|
Research & Development
-â‚©73.9B
|
CAGR 3-Years
-22%
|
CAGR 5-Years
-19%
|
CAGR 10-Years
N/A
|
|
![]() |
Celltrion Inc
KRX:068270
|
Research & Development
-â‚©193.4B
|
CAGR 3-Years
-16%
|
CAGR 5-Years
-11%
|
CAGR 10-Years
N/A
|
|
![]() |
SK Bioscience Co Ltd
KRX:302440
|
Research & Development
-â‚©71.4B
|
CAGR 3-Years
-15%
|
CAGR 5-Years
-21%
|
CAGR 10-Years
N/A
|
|
H
|
Hugel Inc
KOSDAQ:145020
|
Research & Development
-â‚©9.1B
|
CAGR 3-Years
10%
|
CAGR 5-Years
2%
|
CAGR 10-Years
N/A
|
|
P
|
PharmaResearch Co Ltd
KOSDAQ:214450
|
Research & Development
-â‚©21.2B
|
CAGR 3-Years
-46%
|
CAGR 5-Years
-30%
|
CAGR 10-Years
-27%
|
|
![]() |
Alteogen Inc
KOSDAQ:196170
|
Research & Development
-â‚©24.6B
|
CAGR 3-Years
-49%
|
CAGR 5-Years
-31%
|
CAGR 10-Years
-30%
|
ABL Bio Inc
Glance View
ABL Bio, Inc. engages in the development of therapeutic drugs for immuno-oncology and neurodegenerative diseases. The company is headquartered in Seongnam, Gyeonggi-Do. The company went IPO on 2018-12-19. The major products include anti-angiogenesis antibodies anti-tumor targeting antibodies, T cell engager bispecific antibodies (TCEs), dual immune cell targeting bispecific antibodies (DICs), novel immune cell targeting antibodies (NICs), brain disease dual antibodies, antibody-drug conjugates (ADCs) , among others.
See Also
What is ABL Bio Inc's Research & Development?
Research & Development
-73.9B
KRW
Based on the financial report for Dec 31, 2024, ABL Bio Inc's Research & Development amounts to -73.9B KRW.
What is ABL Bio Inc's Research & Development growth rate?
Research & Development CAGR 5Y
-19%
Over the last year, the Research & Development growth was -42%. The average annual Research & Development growth rates for ABL Bio Inc have been -22% over the past three years , -19% over the past five years .